Enanta Pharmaceuticals (ENTA) Depreciation & Amortization (CF) (2012 - 2026)

Enanta Pharmaceuticals has reported Depreciation & Amortization (CF) for 15 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) changed 0.5% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.9 million (up 55.86% YoY), and the FY2025 full-year result was $4.6 million, up 96.32% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $1.2 million, down from $1.2 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $1.3 million in Q3 2025, with the low at $479000.0 in Q3 2024.
• Historically, Depreciation & Amortization (CF) has averaged $819117.6 across 5 years, with a median of $669000.0 in 2023.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) sank 34.49% — and 2025, when it jumped 168.06%.
• Enanta Pharmaceuticals' Depreciation & Amortization (CF) stood at $511000.0 in 2022, then gained by 25.64% to $642000.0 in 2023, then surged by 38.47% to $889000.0 in 2024, then soared by 38.36% to $1.2 million in 2025, then fell by 1.71% to $1.2 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.2 million (Q1 2026), $1.2 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.